Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Joshua J Neumiller1
Travis E Sonnett2
Lindy D Wood1
Stephen M Setter1
R Keith Campbell2

1Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USA

Abstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduction, reductions in body weight, and the drug's low risk for hypoglycemic events when used as monotherapy. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA1c and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.

Keywords: incretin analog, incretin effect, liraglutide, diabetes

Introduction
The burden of diabetes continues to grow, both globally to more than 220 million people worldwide with diabetes1 and in the US, where more than 23.6 million people have the disease.2 Although numerous interventions and medications exist to treat diabetes, less than half of adults in the US with diabetes are able to reach the target glycosylated hemoglobin A1c (HbA1c) level, as set by the American Diabetes Association (ADA), of less than 7% for most patients.3,4 Attaining and maintaining glycemic control in type 2 diabetes mellitus (T2DM) is complicated by disease progression and continued β-cell deterioration.5 Benefits of intensive glucose control include a reduction in microvascular complications, as well as the so-called “legacy effect”. This effect refers to the results of a 10-year follow-up study to the United Kingdom Prospective Diabetes Study, which found that intensive glucose control in newly diagnosed T2DM patients provided long-term benefits on cardiovascular outcomes and mortality, even if intensive control was not sustained in the long term.6 Considering these findings, and that 18% of patients developed a diabetes-related complication within 6 years of diagnosis in the United
Kingdom Prospective Diabetes Study, it is clear that glycemic control starting at the time of T2DM diagnosis is important. While lifestyle modifications, including diet and exercise, were once the initial treatment for patients with T2DM, it is now recognized that these interventions are insufficient for most patients, and pharmacotherapy should not be delayed. Thus, the initial management of a patient presenting with T2DM consists of both lifestyle modification and medication, most specifically metformin, as recommended by the ADA. While monotherapy may suffice in the short term, most patients will need polypharmacy to achieve and sustain glycemic control. The ADA recommends initial combination therapy in newly diagnosed patients with an HbA1c of >8.5%, while a consensus panel for the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) is even more aggressive, recommending dual therapy for patients with an HbA1c between 7.6% and 9%, and triple therapy or insulin for those with an initial HbA1c of >9%.

Because the choice of initial therapy and adjunctive therapy for intensification is increasingly individualized to the patient, agents that were once viewed solely as add-on therapy are now being considered much earlier in the course of treatment. Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are examples of such agents. The AACE/ACE diabetes algorithm recommends monotherapy for patients with an initial HbA1c of 6.5%–7.5%. While metformin is the preferred initial agent, GLP-1 receptor agonists, DPP-4 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors are included as alternatives. For patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 agonist or a DPP-4 inhibitor, citing their efficacy and safety profiles, over thiazolidinediones or sulfonylureas.

Following initial treatment with metformin, the ADA, in contrast, recommends intensification with either basal insulin or a sulfonylurea (both Tier 1, or well validated therapies), pioglitazone or a GLP-1 agonist (both Tier 2, or less well validated therapies). Not only have such treatment algorithms changed in recent years to recommend GLP-1 agonists earlier, but package labeling is also changing to expand their use. Exenatide, the GLP-1 agonist approved by the Food and Drug Administration (FDA) in 2005 for combination therapy, received an indication for monotherapy in 2009.

This relatively new class of GLP-1 agonists has gained increasing use for a variety of reasons. Agents which mimic the incretin system, such as GLP-1 agonists, have a low incidence of hypoglycemia, often cause weight loss, and may preserve β-cells or even stimulate their proliferation. In addition to the approval of exenatide, liraglutide was approved by the FDA in January 2010. This paper will provide an overview of liraglutide and attempt to compare this new incretin analog with exenatide in terms of efficacy, safety, and utility in the treatment of patients with T2DM.

Methods
A MEDLINE search (1966 – February 2010) was conducted with the key words “liraglutide” and “incretin therapies” for clinical trials and pertinent review articles published in English. References of identified articles were searched for additional relevant sources. Abstracts from the ADA and European Association for the Study of Diabetes annual meetings presented in 2006, 2007, 2008, and 2009 were also searched for relevant data. English language articles pertinent to the pharmacology, pharmacokinetics, efficacy, safety, and patient-related outcomes of liraglutide treatment were reviewed. Six Phase III clinical trials from the Liraglutide Effects and Action in Diabetes (LEAD) program have been published. Reports on patient-reported outcomes and quality of life measures have also been published and are discussed herein.

Pharmacology
A role for an intestinal mediator of insulin secretion was initially conceived by the observation that the oral intake of glucose resulted in a greater insulin response when compared with intravenous glucose administration. This “incretin effect” is now known to be due to the stimulation of insulin release by the oral intake of nutrients which results in insulin secretion above and beyond the insulin release induced by increased blood glucose concentrations alone. The incretin effect is now recognized as being responsible for approximately 60% of the insulin response to a given meal. Of clinical significance, the incretin effect has been shown to be greatly impaired in patients with T2DM. The incretin effect is primarily attributed to 2 incretin hormones, ie, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is a 30-amino acid peptide released from L-cells of the intestine in response to a meal, and GIP is released by duodenal cells of the proximal small bowel. GLP-1 secretion is known to be deficient in patients with T2DM, and GLP-1 infusion has been shown experimentally to lower glucose levels via enhanced glucose-dependent insulin secretion in subjects with T2DM. Further study with GLP-1 in subjects with T2DM has demonstrated beneficial effects of GLP-1 on decreasing inappropriate
glucagon secretion,25,26 slowing of gastric emptying,27,28 and increased satiety and decreased food intake.29

While GLP-1 has demonstrated clinical utility in the management of patients with T2DM, endogenous GLP-1 is rapidly degraded by the enzyme DPP-4, resulting in a GLP-1 half-life of approximately 1–2 minutes.30 The development of DPP-4 resistant GLP-1 analogs has been one strategy by which to utilize the beneficial effects of GLP-1 in patients with T2DM. Liraglutide is the newest incretin analog currently available in the US, which is approved for once-daily administration.13

Liraglutide is the newest incretin analog currently available in the US, which is approved for once-daily administration.13 In vitro studies indicate that liraglutide retains affinity for GLP-1 receptors despite these structural modifications.31 The addition of the C16 acyl chain allows for noncovalent binding to albumin, both hindering DPP-4 access to the molecule and contributing to a prolonged half-life and duration of action.32

Pharmacokinetics

The structure of liraglutide makes it kinetically unique when compared with the related compound exenatide; liraglutide incorporates a palmitate side chain at position 26 using a γ-glutamic acid spacer.33,34 This change allows for 99% albumin binding when compared with natural GLP-1, allowing liraglutide to escape glomerular filtration and extend its duration of action. Liraglutide is detected in the urine and feces as metabolites, and is hepatically metabolized and eliminated via the liver and kidneys.

The pharmacokinetic profile of liraglutide makes it a desirable agent for the treatment of T2DM, given the extended time to maximum plasma concentration (Tmax) and half-life (t1/2). In an initial study performed by Elbrond et al, 72 healthy male subjects received 8 consecutive subcutaneous doses (1.25–20.0 μg/kg per dose) of liraglutide.35 Results from this study reported a Tmax of 9–12 hours after dosing, and a plasma t1/2 of elimination of 11–15 hours.35 In a study of 30 healthy male subjects receiving 5 consecutive subcutaneous doses (1.25–12.5 μg/kg per dose) of liraglutide, the reported Tmax was 10–14 hours, while the plasma t1/2 of elimination was 11–13 hours.34 Further kinetic studies were performed utilizing liraglutide in a multi-day fashion with different administration times. One study was performed in 11 subjects with T2DM, administering 10 μg/kg subcutaneously once daily at bedtime for 1 day.36 The Tmax was found to be 10–14 hours, consistent with previous studies, while the plasma t1/2 was found to be 6–14 hours. A second study was performed with liraglutide, administering 6 μg/kg subcutaneously every morning over a 7-day period in 13 T2DM subjects.37 Study results reported a Tmax of 7.1–13.1 hours, and a steady-state plasma t1/2 of 17.9 hours.

Liraglutide was also examined in clinical trials to determine if normal dosing pharmacokinetics would be impacted in both renally and hepatically impaired subjects. Jacobsen et al performed a study in 30 subjects, comprising 24 with varying degrees of renal impairment and 6 healthy subjects, in which 0.75 mg of liraglutide was administered subcutaneously, with 72-hour follow-up blood sampling.38 Results from this study found that liraglutide did not adversely impact serum creatinine in mild-to-severe renal impairment, and was not associated with an increased risk of adverse events in this study population. A meta-analysis was performed examining the Phase III LEAD studies, looking at the impact of liraglutide on serum creatinine levels.39 When compared with normal subjects, no significant change in serum creatinine occurred with either 1.2 mg daily or 1.8 mg daily dosing; this is considered to be due to the modification of liraglutide’s chemical structure when compared with natural GLP-1. Liraglutide was also evaluated in 24 subjects with mild, moderate, severe, or no hepatic impairment.40 Subjects were administered 0.75 mg of liraglutide as a single dose, and were evaluated after a 72-hour period to determine if hepatic impairment influenced liraglutide’s kinetic and safety profile.

When compared with exenatide, there are several differences that may be advantageous when considering the use of liraglutide. Exenatide was directly compared with liraglutide in the LEAD-6 trial to determine the efficacy and safety of each agent.41 Subjects were administered either 1.8 mg/day of liraglutide (202 subjects) or 10 μg twice daily of exenatide (187 subjects) for a period of 26 weeks. It was found that liraglutide maintained steady-state plasma levels 24 hours after administration, while exenatide peaked and returned to baseline plasma levels 10–12 hours following administration. Liraglutide was also found to have minimal impact on renal function due to its chemical structure, while exenatide is primarily eliminated through the kidney, and is not recommended for use in severe renal impairment or end-stage renal disease.1

Clinical trials

The LEAD program comprises 6 randomized, controlled, double-blind Phase III clinical studies in participants with T2DM inadequately controlled with lifestyle and dietary interventions or oral antidiabetic therapies. Table 1 provides a summary of select efficacy endpoints reported from the six LEAD studies discussed individually below.42-47
Table I Select efficacy outcomes from the Liraglutide Effects and Action in Diabetes (LEAD) trials

| Pts | Treatment       | Intervention | Treatment period (weeks) | HbA1c Change (%) | Achievement of HbA1c < 7% (%) | FPG change (mg/dL) | PPG change (mg/dL) | BW change (kg) |
|-----|-----------------|--------------|--------------------------|------------------|-------------------------------|-------------------|-------------------|-----------------|
| LEAD-1<sup>a</sup> | 1041 | Glim 2–4 mg/day | Lir 0.6 mg/day | 26 | −0.6<sup>h</sup> | 24<sup>a</sup> | −13.0<sup>h</sup> | −32.4<sup>h</sup> | +0.7<sup>h</sup> |
|     |                 |              | Lir 1.2 mg/day |                 |                               |                   |                   |                  |
|     |                 |              | Lir 1.8 mg/day |                 |                               |                   |                   |                  |
|     |                 |              | Ros 4 mg/day   |                 | −0.44<sup>a</sup> | 22              | −15.8              | −32.4            | +2.1            |
|     |                 |              | Placebo        |                 | +0.23            | 8                 | +18.2              | −7.2            | −0.1            |
| LEAD-2<sup>a</sup> | 1091 | Met 1 g twice daily | Lir 0.6 mg/day | 26 | −0.7<sup>h</sup> | 28.0              | −19.8              | −30.6            | −1.8<sup>h</sup> |
|     |                 |              | Lir 1.2 mg/day |                 | −1.0<sup>h</sup> | 35.3              | −28.8              | −41.4            | −2.6<sup>h</sup> |
|     |                 |              | Lir 1.8 mg/day |                 | −1.0<sup>h</sup> | 42.4              | −30.6              | −46.8            | −2.8<sup>h</sup> |
|     |                 |              | Glim 4 mg/day  |                 | −1.0<sup>e</sup> | 36.3              | −23.4              | −45.0            | +1.0            |
|     |                 |              | Placebo        |                 | +0.1              | 10.8              | +7.2              | −10.8           | −1.5            |
| LEAD-3<sup>a</sup> | 746  | Diet/exercise 50% maximum | Lir 1.2 mg/day | 52 | −0.84<sup>i</sup> | 42.8<sup>h</sup> | −15.1<sup>i</sup> | −30.8            | −2.1<sup>i</sup> |
|     |                 |              | Lir 1.8 mg/day |                 | −1.14<sup>i</sup> | 50.9<sup>h</sup> | −25.6              | −37.4<sup>i</sup> | −2.5<sup>i</sup> |
|     |                 |              | Glim 8 mg/day  |                 | −0.51            | 27.8              | −5.2              | −24.5           | +1.1            |
| LEAD-4<sup>a</sup> | 533  | Met 1 g twice daily | Lir 1.2 mg/day | 26 | −1.48<sup>h</sup> | 57.5<sup>a</sup> | −40<sup>j</sup> | −47<sup>i</sup> | −1.0<sup>h</sup> |
|     |                 |              | Lir 1.8 mg/day |                 | −1.48<sup>h</sup> | 53.7<sup>a</sup> | −44<sup>i</sup> | −49<sup>i</sup> | −2<sup>o</sup>  |
|     |                 |              | Placebo        |                 | −0.54            | 28.1              | −8                | −14            | +0.6            |
| LEAD-5<sup>a</sup> | 581  | Met 1 g twice daily | Lir 1.8 mg/day | 26 | −1.33<sup>ab</sup> | 53.1<supactice</sup> | −27.9              | −32.6            | −1.8<sup>ab</sup> |
|     |                 |              | Glim 4 mg/day  |                 | −1.09            | 45.8              | −32.2              | −29.0            | +1.6            |
|     |                 |              | Placebo        |                 | −0.24            | 15.5              | +9.5              | −0.5            | −0.4            |
| LEAD-6<sup>a</sup> | 464  | Met SU          | Lir 1.8 mg/day | 26 | −1.12<sup>h</sup> | 54<sup>j</sup> | −29.0<sup>o</sup> | NR<sup>l</sup> | −3.2 |
|     |                 |              | SU Exen 10 µg bid |                 | −0.79<sup>i</sup> | 43 | −10.8<sup>o</sup> | NR<sup>l</sup> | −2.9 |

Notes: <sup>a</sup>P < 0.0001 versus placebo; <sup>b</sup>P < 0.0005 versus comparator; <sup>c</sup>P = 0.0005 versus comparator; <sup>d</sup>P < 0.0001 versus comparator; <sup>e</sup>P < 0.01 versus comparator; <sup>f</sup>P < 0.0043 versus comparator; <sup>g</sup>P = 0.0022 versus comparator; <sup>h</sup>Noninferior to active comparator; <sup>i</sup>P < 0.02 versus placebo; <sup>j</sup>P < 0.01 versus placebo; <sup>k</sup>P = 0.01 versus placebo; <sup>l</sup>P = 0.0014 versus placebo; <sup>m</sup>P = 0.0007 versus placebo; <sup>n</sup>P = 0.027 versus placebo; <sup)o</sup>P = 0.0038 versus comparator; <sup>p</sup>P < 0.05 versus placebo; <sup>q</sup>P = 0.0139 versus comparator; <sup>r</sup>P = 0.0015 versus comparator; Average reduction reported to be significantly greater for exenatide when compared with liraglutide.

Abbreviations: HbA1c, hemoglobin A1c; BW, body weight; Exen, exenatide; FPG, fasting plasma glucose; Glim, glimepiride; Lir, liraglutide; NR, not reported; OAD, oral antidiabetic drug; PPG, postprandial glucose; Pts, participants randomized; Ros, rosiglitazone; SU, sulfonylurea.

Liraglutide versus rosiglitazone as add-on to baseline glimepiride

LEAD-1 was a 26-week, randomized, double-dummy trial in 1041 patients with T2DM. The objective of the study was to compare the addition of liraglutide to glimepiride therapy with the addition of rosiglitazone to baseline glimepiride. Participants had a mean baseline HbA1c of 8.4% and a mean age of 56.1 years. Participants received liraglutide 0.6 mg/day, 1.2 mg/day, or 1.8 mg/day in combination with glimepiride, placebo plus glimepiride (2–4 mg/day), or rosiglitazone 4 mg/day plus glimepiride. Mean HbA1c was reduced by −1.08% and −1.13% with liraglutide 1.2 mg and 1.8 mg, respectively. Participants receiving rosiglitazone experienced a mean HbA1c reduction of −0.44%, and glimepiride monotherapy resulted in a mean HbA1c increase of 0.23% (P < 0.0001). Of those treated with liraglutide 1.2 mg plus glimepiride, 22% reached an HbA1c less than 6.5%, with 21% reaching an HbA1c less than 6.5% with liraglutide 1.8 mg plus glimepiride. In contrast, 4% of those on glimepiride monotherapy and 10% of subjects treated with rosiglitazone plus glimepiride reached an HbA1c below 6.5% (P < 0.0003).

Liraglutide versus glimepiride as add-on to baseline metformin

LEAD-2 was a randomized, double-blind study that enrolled 1091 participants with T2DM. Participants received liraglutide 0.6 mg, 1.2 mg, or 1.8 mg once daily added to metformin 1 g twice daily, placebo plus metformin, or glimepiride 4 mg/day added to metformin. Mean HbA1c reductions of −0.7%, −1.0%, and −1.0% were observed with liraglutide 0.6 mg, 1.2 mg, and 1.8 mg in combination with metformin, respectively. Those receiving metformin monotherapy experienced a mean HbA1c increase of 0.1%, with a decrease of −1.0% seen in those receiving glimepiride plus metformin (P < 0.05 versus liraglutide plus metformin versus placebo plus metformin). Weight loss was achieved in all participants receiving liraglutide, compared with a 1.0 kg weight gain observed in those receiving glimepiride (P < 0.0001 for all liraglutide doses when compared with glimepiride). The percentage of patients achieving an HbA1c less than 6.5% was 11.3% in the liraglutide 0.6 mg plus metformin group, 19.8% in the liraglutide 1.2 mg plus metformin group, and 24.6% in
the liraglutide 1.8 mg plus metformin group, compared with 4.2% of those treated with placebo plus metformin, and 22.2% of those treated with glimepiride plus metformin (P < 0.02 for all liraglutide doses when compared with placebo).

Liraglutide versus glimepiride as monotherapy
The LEAD-3 study enrolled 746 patients with T2DM and a mean baseline HbA1c of 8.2%. This Phase III, double-blind, parallel-treatment study involved a head-to-head comparison of monotherapy with 1.2 mg/day or 1.8 mg/day of liraglutide or glimepiride 8 mg/day. Any previous oral antidiabetic drugs (up to half the maximal dose) were discontinued at randomization prior to study drug initiation. At 52 weeks of therapy, mean HbA1c reductions from baseline of −0.84% (P = 0.0014 versus glimepiride) and −1.4% (P < 0.0001 versus glimepiride) were seen with liraglutide 1.2 mg and 1.8 mg, compared with a reduction of −0.51% for glimepiride. Twenty-seven percent of patients on liraglutide 1.8 mg and 16% of patients on glimepiride attained an HbA1c less than 6.5%. Decreases in body weight observed were −2.1 kg and −2.5 kg for liraglutide 1.2 mg and 1.8 mg, respectively (P = 0.0001 versus glimepiride for both doses). In contrast, participants receiving glimepiride experienced an average weight gain of 1.1 kg.

Liraglutide as add-on to baseline metformin and rosiglitazone
LEAD-4 was a 26-week, placebo-controlled trial enrolling 533 patients with T2DM and a mean baseline HbA1c of 8.3%. LEAD-4 assessed the effect of adding liraglutide 1.2 mg or 1.8 mg to baseline metformin 1 g twice daily plus rosiglitazone 8 mg/day. Liraglutide addition resulted in mean HbA1c reductions of −1.48% for both liraglutide doses compared with −0.54% observed with the addition of placebo (P = 0.0001). An HbA1c less than 6.5% was achieved in 35% and 37% of patients receiving liraglutide 1.2 mg and 1.8 mg, respectively. Liraglutide 1.2 mg and 1.8 mg treatment resulted in reductions in fasting plasma glucose (−40 mg/dL and −43 mg/dL, respectively) and postprandial glucose levels (−49 mg/dL and −47 mg/dL, respectively). Patients receiving placebo experienced a mean increase in body weight of 0.6 kg compared with a mean weight loss of −1.0 kg and −2.0 kg for liraglutide 1.2 and 1.8 mg (P < 0.05 versus placebo for both liraglutide doses).

Liraglutide versus glargine as add-on to baseline metformin and glimepiride
LEAD-5 aimed to compare liraglutide with insulin glargine as add-on therapy to metformin and glimepiride. LEAD-5 enrolled a total of 581 patients with T2DM with a mean baseline HbA1c of 8.2%. Participants received liraglutide 1.8 mg/day, liraglutide placebo, or insulin glargine in addition to metformin 1 g twice daily and glimepiride (2–4 mg/day) for a duration of 26 weeks. The dose of insulin glargine was individually titrated according to a patient-driven algorithm, with a mean dose of 24 units per day reported at the end of the trial in the insulin glargine arm. Mean HbA1c values were decreased −1.33%, −0.24%, and −1.09% with the addition of liraglutide, placebo, and insulin glargine, respectively (P < 0.05 for liraglutide versus placebo and insulin glargine). An HbA1c below 6.5% was achieved in 37.1% of patients treated with liraglutide, 10.9% of those treated with placebo (P < 0.0001 versus liraglutide), and 23.6% of patients in the insulin glargine group (P = 0.0001 versus liraglutide). A mean body weight reduction of −1.81 kg was reported in the liraglutide group (P < 0.0001 versus glargine; P = 0.0001 versus placebo), with a mean weight loss of −0.42 kg in the placebo group, and a 1.62 kg weight gain seen in the insulin glargine group.

Liraglutide versus exenatide as add-on to baseline metformin and/or a sulfonylurea
LEAD-6 was a 26-week trial in 464 patients inadequately treated with metformin and/or a sulfonylurea with a mean baseline HbA1c of 8.2%. This trial aimed to compare liraglutide 1.8 mg/day to exenatide 10 µg twice daily as add-on therapy. HbA1c reductions of −1.12% for liraglutide and −0.79% for exenatide were observed (P < 0.0001). A target HbA1c less than 6.5% was achieved in 35% of those treated with liraglutide versus 21% for patients receiving exenatide (P < 0.0001). Changes in body weight were similar in both groups with no statistical differences in weight change between the liraglutide and exenatide treatment groups. Weight reductions of −3.2 kg and −2.9 kg for liraglutide and exenatide were observed, respectively.

Additional clinical endpoints
Clinical studies with liraglutide have also demonstrated potential benefits of therapy on β-cell function and the cardiovascular system. One study utilized a graded glucose protocol to assess the effects of a single liraglutide dose of 7.5 µg/kg on insulin secretion. Insulin secretion increased with elevation in blood glucose in all groups, however liraglutide treatment resulted in a more pronounced insulin response which was similar to that observed in healthy control subjects. Other clinical studies have shown improvements in glucose-induced insulin secretion, β-cell sensitivity, and suppression of
24-hour glucagon secretion following 1 week of therapy, and sustained β-cell sensitivity to glucose over 12 weeks of therapy. Regarding the effects of liraglutide treatment on cardiovascular health, statistically significant decreases in systolic blood pressure, ranging from 2 to 7.9 mmHg, have been observed in clinical trials. The mechanism resulting in the observed reduction in systolic blood pressure is unknown, but appears unrelated to concomitant weight loss.

Early data additionally indicates liraglutide treatment may also decrease cardiovascular markers such as PAI-1 and BNP, but the clinical implications, either positive or detrimental, of these findings are unknown.

### Safety and tolerability

#### Hypoglycemia

Of paramount importance in any newly approved drug used to treat T2DM is the likelihood of hypoglycemia, when used as mono-, dual-, or even as part of a triple-therapy regimen. In the LEAD trials, a minor hypoglycemic event was defined as a plasma glucose concentration of <56 mg/dL that was resolved with self-treatment, and a major hypoglycemic event requiring third party assistance. Note that in LEAD-1, self-treatment was the sole criteria used to classify a hypoglycemic event as minor. As expected, trials utilizing combination sulfonylurea therapy resulted in the highest incidence of hypoglycemia. LEAD-1 involved patients on concurrent sulfonylurea therapy (glimepiride). In this trial, the percentage of patients experiencing minor hypoglycemia was reported as glimepiride monotherapy (placebo) 2.6%, 0.17 events/subject-year; liraglutide 0.6 mg, 5.2%, 0.17 events/subject-year; liraglutide 1.2 mg 9.2%, 0.51 events/subject-year; liraglutide 1.8mg, 8.1%, 0.47 events/subject-year; and rosiglitazone 4.3%, 0.12 events/subject-year. Table 2 provides a summary of adverse event findings from the LEAD program. Furthermore, in the 1.8 mg liraglutide plus glimepiride cohort, one major hypoglycemic event occurred.

In LEAD-2, the percentage of patients experiencing minor hypoglycemia was low in the placebo and liraglutide cohorts, roughly 3%, while 17% of subjects receiving glimepiride reported an incidence of minor hypoglycemia. Major hypoglycemic events did not occur in LEAD-2. There were

### Table 2: Adverse drug event rates in Liraglutide Effects and Action in Diabetes (LEAD) trials

| Study   | Drug                  | Patients experiencing minor hypoglycemic events (%) | Major hypoglycemic events (n) | Nausea (%) | Vomiting (%) | GI events (%) | Pancreatitis (number of subjects) | Pulse rate (bpm) | Liraglutide antibody formation (%) |
|---------|-----------------------|-----------------------------------------------------|-------------------------------|------------|--------------|--------------|-----------------------------------|-----------------|-----------------------------------|
| LEAD-1  | Liraglutide 0.6 mg    | 5.2                                                 | 0                             | NR         | NR           | NR           | 1                                 | +2–4<sup>ab</sup> | 9–13<sup>a</sup>                 |
|         | Liraglutide 1.2 mg    | 9.2<sup>cd</sup>                                    | 0                             | NR         | NR           | NR           | 0                                 |                 |                                   |
|         | Liraglutide 1.8 mg    | 8.1<sup>a</sup>                                    | 1                             | NR         | NR           | NR           | 0                                 |                 |                                   |
|         | Rosiglitazone 4 mg    | 4.3                                                 | 0                             | NR         | NR           | NR           | 0                                 |                 |                                   |
|         | Placebo               | 2.6                                                 | 0                             | 1.8        | NR           | NR           | 0                                 |                 | –1<sup>a</sup>                  |
| LEAD-2  | Liraglutide 0.6 mg    | 3<sup>a</sup>                                       | 0                             | 11         | 5–7<sup>a</sup> | 35           | 0                                 | +<sup>2–3</sup>e | NR                                |
|         | Liraglutide 1.2 mg    | 16                                                  | 0                             | 40         | 1            | NR           |                                   |                 |                                   |
|         | Liraglutide 1.8 mg    | 19                                                  | 0                             | 44         | 0            | NR           |                                   |                 |                                   |
|         | Glimepiride 4 mg      | 17                                                  | 0                             | NR         | 1            | 17           | 1                                 | +1              | NA                                |
|         | Placebo               | 3                                                   | 0                             | NR         | 1            | 17           | 0                                 | +1              | NA                                |
| LEAD-3  | Liraglutide 1.2 mg    | 12<sup>f</sup>                                      | 0                             | 27.5<sup>l</sup> | 9.3          | 49           | 1                                 | +<sup>3.2</sup> | NR                                |
|         | Liraglutide 1.8 mg    | 8<sup>g</sup>                                       | 0                             | 29<sup>h</sup> | 12.4         | 51           | 1                                 | +1              | NR                                |
|         | Glimepiride 8 mg      | 24                                                  | 0                             | 8.5        | 3.6          | 26           | 0                                 | –0.4            | NA                                |
| LEAD-4  | Liraglutide 1.2 mg    | 9<sup>i</sup>                                       | 0                             | 29         | 7            | 45           | 0                                 | +2              | 4.1                               |
|         | Liraglutide 1.8 mg    | 7.9<sup>j</sup>                                     | 0                             | 40         | 17           | 56           | 0                                 | +3              | 6.7                               |
|         | Placebo               | 5.1                                                 | 0                             | NR         | NR           | 19           | 0                                 | –0.5            | 0                                 |
| LEAD-5  | Liraglutide 1.8 mg    | 27.5                                                | 5                             | 13.9       | 6.5          | NR           | 0                                 | +2.62           | 9.8                               |
|         | Insulin glargine      | 28.9                                                | 0                             | 1.3        | 0.4          | NR           | 0                                 | +0.08           | NA                                |
|         | Placebo               | 16.7                                                | 0                             | 3.5        | 3.5          | NR           | 0                                 | –0.93           | NA                                |
| LEAD-6  | Liraglutide 1.8 mg    | 26<sup>k</sup>                                      | 0                             | 25.5       | 6.0          | 45.5         | 1                                 | +3.28<sup>h</sup> | NR                                |
|         | Exenatide 10 µg bid   | 34                                                  | 2                             | 28.0       | 9.9          | 42.7         | 0                                 | +0.69           | NA                                |

**Notes:**<sup>a</sup>Reported composite for all liraglutide doses tested; <sup>b</sup>P = 0.0022 versus placebo; <sup>c</sup>P = 0.000049 versus comparator; <sup>d</sup>P = 0.048 versus placebo; <sup>e</sup>P = 0.0065 versus comparator; <sup>f</sup>P < 0.001 versus comparator; <sup>g</sup>P < 0.003 for 0.6 mg and 1.2 mg liraglutide groups versus comparator; <sup>h</sup>P = 0.0027 versus comparator; <sup>i</sup>P = 0.004 versus placebo; <sup>j</sup>P = 0.0131 versus comparator; <sup>k</sup>P = 0.0012 versus comparator.

**Abbreviations:** bid, twice daily; bpm, beats per minute; GI, gastrointestinal; NA, not applicable; NR, not reported.
a low percentage of patients reporting minor hypoglycemic events in LEAD-3, with 8% of the subjects in the liraglutide 1.8 mg group (0.25 events per year) and 12% of subjects in the 1.2 mg group experiencing minor hypoglycemic events (0.3 events per year). Twenty-four percent of subjects in the glimepiride group reported minor hypoglycemic events while no major hypoglycemic events occurred in any of the groups in this 52-week trial.

Minor hypoglycemia was reported in LEAD-4 at rates of 9%, 7.9%, and 5.1% of subjects in the 1.2 mg liraglutide, 1.8 mg liraglutide, and placebo groups, respectively. No major hypoglycemic events were reported. In LEAD-5, 27.4% of the patients receiving liraglutide experienced at least 1 episode of minor hypoglycemia (1.2 events/subject/year), while 28.9% (1.3 events/subject/year) and 16.7% (1.0 events/subject/year) experienced minor hypoglycemia in the insulin glargine and placebo groups, respectively. In the liraglutide group, 5 subjects reported a major hypoglycemic episode, with no major hypoglycemic events reported in the other two cohorts.

In the open-label 26-week trial known as LEAD-6, minor hypoglycemia occurred in 26% and 34% of the liraglutide and exenatide groups, respectively; correlating to event rates of 1.9 (liraglutide) and 2.6 (exenatide) events per subject per year. Two cases of major hypoglycemia occurred in subjects exposed to exenatide and a sulfonylurea.

**Gastrointestinal adverse events**

In the LEAD-1 trial, incomplete data were provided for all arms of the study in regard to gastrointestinal (GI) side effects. The most complete data reveal that nausea was highest in the liraglutide 1.2 mg cohort (10.5%) compared with an event rate of 1.8% in the placebo group. Additionally, 4.4% and 7.9% of those in the 1.2 mg liraglutide group experienced vomiting and diarrhea, respectively.

The LEAD-2 trial involved subjects on a wide range of oral therapies that included metformin, sulfonylureas, repaglinide, or some combination of these listed medications. GI adverse events were pronounced in this trial, with 35% of the subjects in the 0.6 mg liraglutide group experiencing GI side effects, including nausea, vomiting, and diarrhea, with 40% and 44% experiencing these GI-related adverse events in the 1.2 mg and 1.8 mg groups, respectively. This is in comparison with 17% of the placebo-treated group reporting GI-associated adverse events. Five percent (36 subjects) of those receiving any dose of liraglutide withdrew from the study due to GI-related adverse events.

In LEAD-3, nausea occurred in 27.5%, 29.3%, and 8.5% of participants in the 1.2 mg liraglutide, 1.8 mg liraglutide, and glimepiride groups, respectively. Vomiting occurred in 3.6% of subjects receiving glimepiride, while this side effect occurred in 9.3% and 12.4% of those receiving 1.2 mg and 1.8 mg of liraglutide, respectively. Diarrhea was reported by 15.5%, 18.7%, and 8.9% of participants in the 1.2 mg liraglutide, 1.8 mg liraglutide, and glimepiride groups, respectively. A total of 6 participants (1.2%) receiving liraglutide withdrew from the study due to vomiting, while a total of 17 participants (3.4%) receiving liraglutide withdrew for any GI-related complaint. In the 26-week study known as LEAD-4, 29% of subjects receiving 1.2 mg liraglutide experienced nausea while 40% of subjects in the 1.8 mg liraglutide group reported this adverse event. Vomiting was reported by 7% and 17% of subjects in the 1.2 mg and 1.8 mg liraglutide groups, respectively. When all GI adverse events were grouped (nausea, vomiting, diarrhea), 19% of those receiving placebo and 45% and 56% of those receiving 1.2 mg and 1.8 mg of liraglutide, respectively, reported GI-related complaints. GI adverse events contributed to 5 withdrawals (3% of participants) in the liraglutide 1.2 mg group and 19 (10.7% of participants) in the liraglutide 1.8 mg group.

Nausea occurred in 13.9% of those receiving liraglutide, 3.5% in placebo arm, and 1.3% of participants in the insulin glargine group in LEAD-5. In this trial, diarrhea was reported in 10%, 5.3%, and 1.3% in the liraglutide, placebo, and insulin glargine groups, respectively. Vomiting occurred in 6.5%, 3.5%, and 0.4% in the liraglutide, placebo, and insulin glargine groups, respectively. Dyspepsia was also reported in this trial, with 6.5%, 0.9%, and 1.7% of subjects in the liraglutide, placebo, and insulin glargine groups, respectively, experiencing this GI-related adverse event. Four subjects in LEAD-5 receiving liraglutide withdrew from the study due to GI-related adverse events. LEAD-6 reported similar rates of GI-related adverse events between the liraglutide and exenatide groups. Overall, GI adverse events occurred in 45.5% and 42.7% of liraglutide- and exenatide-treated subjects, respectively, with nausea being the most frequently reported event. Nausea tended to resolve over time with both therapies, however, with 2.5% of the liraglutide group reporting nausea at week 26 compared with 15.8% of those receiving exenatide therapy. Vomiting occurred in 6.0% and 9.9% of the liraglutide and exenatide groups, respectively.

From the above data it can be seen that nausea is a frequent adverse event in subjects receiving liraglutide. However, nausea was most pronounced in the first 4 weeks of therapy, with symptoms generally dissipating over the remainder of the study period in all trials.
Pulse rate
The effects of liraglutide on pulse rate ranged from an
decrease of 2–4 beats per minute (bpm) in subjects receiv-
ing liraglutide ($P \leq 0.002$ versus placebo; $P < 0.01$ versus
rosiglitazone), with pulse increasing by a mean 1 bpm in
subjects receiving rosiglitazone, and pulse decreasing by
a mean 1 bpm in the placebo group. In the LEAD-2 trial,
pulse rates increased by a mean 2–3 bpm in those receiving
liraglutide, compared with a 1 bpm increase in the glimepiride
and placebo groups. The mean pulse rate in LEAD-3
increased by 0.4, 3.2, and 1.6 bpm for the glimepiride group
and the 1.2 mg and 1.8 mg liraglutide groups, respectively.
Pulse rate increased by 2 bpm in subjects receiving liraglutide
in LEAD-4, with mean pulse rates increasing by 3 bpm in
those receiving liraglutide 1.8 mg. Pulse rate increased by
a mean of 3.28 bpm in the liraglutide group compared with
0.69 bpm in the exenatide group.

Pancreatitis
Pancreatitis has been reported in clinical trials with lira-
glutide. In LEAD-1, one subject receiving liraglutide
0.6 mg developed pancreatitis but successfully completed
the trial. Two subjects withdrew from the LEAD-2 study
after developing pancreatitis, 1 receiving liraglutide and 1
receiving glimepiride. In LEAD-3 developed pancreatitis, with one complet-
ing the trial. No cases of pancreatitis were reported in the
26-week LEAD-4 or LEAD-5 trials. Likewise, no cases of
acute pancreatitis were reported in LEAD-6; however, 1 case
of mild pancreatitis occurred in a subject receiving liraglutide
who subsequently completed the 26-week trial.

Anti-liraglutide antibodies
In LEAD-1, 9%–13% of subjects exposed to liraglutide
during the 26-week trial developed anti-liraglutide antibod-
ies. The LEAD-2 and LEAD-3 trials did not measure the
development of liraglutide antibody formation. In LEAD-4,
6 subjects in the liraglutide 1.2 mg group and 9 subjects
in the liraglutide 1.8 mg group developed antibodies. In
LEAD-5, 23 subjects (9.8%) of subjects developed anti-
liraglutide antibodies during the 26-week study. Because
the LEAD-6 trial involves an extension phase where subjects
may continue to take liraglutide, antibody determination
will be completed once the trial is complete and after an
appropriate washout period; these data are not currently
available. While the clinical impact of anti-liraglutide
antibodies is unknown at this time, further study of this
phenomenon is warranted.

Additional safety considerations
Study withdrawal rates due to adverse drug events and
event rates for serious adverse events reported in the six
LEAD trials are summarized in Table 3. Interestingly,
injection-related adverse events such as injection site rash,
were not reported in any of the LEAD trials. In addition
to the adverse drug events discussed above, peripheral
edema was reported in the LEAD-4 trial, likely due to
participants also receiving concomitant rosiglitazone. In
this trial, peripheral edema occurred in 5.1%, 1.7%, and
8.0% of the subjects in the 1.2 mg liraglutide, 1.8 mg
liraglutide, and placebo groups, respectively. The LEAD
studies indicate liraglutide to be generally safe, however
the development of rare adverse events is of concern until
patients at heightened risk for developing events such as
pancreatitis can be identified. The safety and tolerability
of liraglutide can only truly be assessed with robust Phase
IV post-marketing data involving long-term treatment with
this novel therapy.

An additional theoretical concern raised in the liraglutide
prescribing information is a warning regarding the observa-
tion of dose-dependent and treatment-duration-dependent
thyroid C-cell tumors witnessed at clinically relevant
exposures in rats and mice. During clinical trials with
liraglutide, calcitonin, a biomarker for the detection of med-
ullary thyroid cancer, was monitored routinely. During the
LEAD program, increases in calcitonin levels did occur in a
slightly higher percentage of patients treated with liraglutide
when compared with controls, however, calcitonin levels
remained within normal ranges. Ultimately, while it is
unknown if this is clinically relevant in humans, liraglutide
is contraindicated in patients with a personal or family his-
tory of medullary thyroid carcinoma, and in patients with
multiple endocrine neoplasia syndrome type 1. The FDA
has requested the establishment of a cancer registry to moni-
tor the annual incidence of medullary thyroid cancer over
the next 15 years.

Administration
Liraglutide was approved in July of 2009 by the European
Commission for marketing consideration to all 27 Euro-
pean Union members. Liraglutide is administered as a
Liraglutide in the management of type 2 diabetes

Injection for once-daily treatment of T2DM, as an adjunct therapy in combination with metformin, a sulfonylurea, or metformin plus a sulfonylurea or thiazolidinedione. The approved dosing for use in Europe is an initial dose of 0.6 mg daily for one week, with a recommended titration to 1.2 mg daily after the first week. The maximum recommended daily dose is 1.8 mg for patients who are not well controlled and who can tolerate the higher titrated dose, although doses as high as 2 mg daily have been used in clinical trials. The LEAD studies found that titrating liraglutide by 0.6 mg weekly improved the tolerability and reduced the occurrence of GI adverse events. Injection site reactions are another concern, and should be monitored for during liraglutide initiation.

Patient-specific considerations

A common problem among T2DM patients is the issue of weight management. Elevated body weight or obesity, and an increased risk of cardiovascular-related complications often increase the medical burden and medication load of the patient. The patient is often prescribed a medication regimen that is counterproductive to weight loss, decreasing treatment satisfaction due to resulting weight gain. Newer GLP-1 agonists, such as exenatide and liraglutide, are associated with weight reduction in healthy and diabetic subjects. A comparative trial of exenatide and liraglutide in T2DM subjects concluded that both exenatide and liraglutide were associated with a significant reduction in body weight when compared with baseline (−2.87 kg and −3.24 kg, respectively). In the LEAD-3 trial, weight loss was reported in both the 1.2 mg and 1.8 mg liraglutide monotherapy groups, with an average loss of −2 kg and −2.5 kg, respectively (P < 0.0001). Reported weight loss occurred during the first 16 weeks, but was sustained throughout the remaining 36 weeks of treatment. After completion of a second 52-week open-label study period, weight reductions of −2.1 kg and −2.7 kg for both the 1.2 mg and 1.8 mg liraglutide

Table 3 Clinical study withdrawal and serious adverse event rates in Liraglutide Effects and Action in Diabetes (LEAD) trials

| Study       | Drug             | Discontinuation due to ADE (%) | Serious adverse events |
|-------------|------------------|--------------------------------|------------------------|
| LEAD-1      | Liraglutide 0.6 mg | 20                             | 3%                     |
|             | Liraglutide 1.2 mg | 34                             | 4%                     |
|             | Liraglutide 1.8 mg | 43                             | 5%                     |
|             | Rosiglitazone 4 mg | 19                             | 3%                     |
|             | Placebo          | 19                             | 3%                     |
| LEAD-2      | Liraglutide 0.6 mg | 32                             | NR                     |
|             | Liraglutide 1.2 mg | 52                             | NR                     |
|             | Liraglutide 1.8 mg | 57                             | NR                     |
|             | Glimepiride 4 mg  | 23.5                           | NR                     |
|             | Placebo          | 4                              | NR                     |
| LEAD-3      | Liraglutide 1.2 mg | 28                             | 16 subjects/18 events  |
|             | Liraglutide 1.8 mg | 24                             | 8 subjects/9 events    |
|             | Glimepiride 8 mg  | 16                             | 13 subjects/17 events  |
| LEAD-4      | Liraglutide 1.2 mg | 44                             | 8 subjects/8 events    |
|             | Liraglutide 1.8 mg | 60                             | 7 subjects/10 events   |
|             | Placebo          | 10.7                           | 12 subjects/13 events  |
| LEAD-5      | Liraglutide 1.8 mg | 48                             | NR                     |
|             | Insulin glargine  | 38.5                           | NR                     |
|             | Placebo          | 5.5                            | NR                     |
| LEAD-6      | Liraglutide 1.8 mg | 70                             | 5.1%                   |
|             | Exenatide 10 µg bid | 69                           | 2.6%                   |

Notes: *Percentage of the total number of subject dropouts who withdrew due to an adverse drug event; †Reported either as a percentage of study subjects or number of subjects and number of events.
Abbreviations: ADE, adverse drug event; NR, not reported.
study groups, respectively, were significant when compared with those receiving glimepiride ($P < 0.0001$). In all LEAD studies completed, liraglutide 1.8 mg daily was associated with reported weight reductions of $-0.2$ kg to $-3.2$ kg over a period of at least 6 months. Of additional interest, an analysis of patients from LEAD-1 and LEAD-2 reported that weight reductions in patients receiving liraglutide were primarily due to reductions in fat mass rather than lean tissue mass. Finally, a trial enrolling healthy, non diabetic patients with a mean baseline BMI of $30–40$ kg/m$^2$ compared the weight effects of liraglutide at doses of $1.2$, $1.8$, $2.4$, and $3$ mg daily, versus orlistat $120$ mg three times daily or placebo. Weight loss in liraglutide subjects was $-4.8$ kg in the $1.2$ mg group ($P = 0.003$), $-5.5$ kg in the $1.8$ mg group ($P < 0.0001$), $-6.3$ kg in the $2.4$ mg group ($P < 0.0001$), and $-7.2$ kg in the $3.0$ mg group ($P < 0.0001$) when compared with baseline.

Quality of life was another indicator of treatment outcome that was evaluated in select clinical trials. Astrup et al found that mean physical function improved in the liraglutide $3.0$ mg group by a score of $6.3$ kg in the $1.8$ mg group ($P < 0.0001$), $-6.3$ kg in the $2.4$ mg group ($P < 0.0001$), and $-7.2$ kg in the $3.0$ mg group ($P < 0.0001$) when compared with baseline.

The pharmacokinetic profile of liraglutide is amenable to once-daily dosing, thus creating a potential advantage in terms of ease of use, with similar improvements in HbA$_1c$ and body weight seen when comparing these two agents. Comparative data with exenatide twice-daily indicate a potential therapeutic advantage for liraglutide in terms of ease of use, with similar improvements in HbA$_1c$ and body weight seen when comparing these two agents.

Discriminant validity is an important clinical consideration, particularly in patients receiving multiple medications for the treatment of T2DM and related comorbidities. Patients often present with resistance to the initiation of an injectable agent, however the potential for weight loss with the incretin mimetics and incretin analogs can be a motivator for some patients. The most recent consensus algorithm released by the ADA and the European Association for the Study of Diabetes lists GLP-1 analogs as a treatment option for consideration as a Tier 2 agent, or “less well-validated therapy”, in T2DM patients. The consensus guideline recommends consideration of GLP-1 agonist therapy in selected clinical situations. One situation in which GLP-1 agonist therapy could be considered is if weight loss is a major consideration and the patient’s HbA$_1c$ level is close to target (<8.0%). The guideline warns, however, that GLP-1 agonist therapy is not indicated for all patients and should be used with caution in those with a history of significant GI disease, such as a diagnosis of gastroparesis, due to a possible exacerbation of such conditions with incretin mimetic therapy. Because postprandial hyperglycemia affects HbA$_1c$ to a greater degree than fasting hyperglycemia, the closer a patient is to their HbA$_1c$ goal, GLP-1 agonists, such as liraglutide, provide a viable treatment option to target postprandial glucose excursions due to their glucose-dependent effects on insulin secretion.

### Conclusion

Clinical trial data from large, controlled studies demonstrate the efficacy and safety of liraglutide in terms of HbA$_1c$ reduction, beneficial effects on body weight, and a low risk for hypoglycemic events when used as monotherapy. Liraglutide is relatively well tolerated, with dose-dependent nausea, vomiting, and diarrhea being the most commonly reported adverse events observed in clinical trials. Clinical trial data in humans indicate that liraglutide may have a role in the treatment of T2DM patients as monotherapy early in the disease process, as well as in combination with metformin, glimepiride, and rosiglitazone in patients inadequately controlled on oral antidiabetic drugs. Comparative data with exenatide twice-daily indicate a potential therapeutic advantage for liraglutide in terms of ease of use, with similar improvements in HbA$_1c$ and body weight seen when comparing these two agents. Data are currently not available comparing liraglutide with once-weekly exenatide currently under Phase III study, however. Questions do remain regarding the safety of this agent in terms of risk of pancreatitis and medullary thyroid carcinoma. While the risk of such events is assumed to be small, vigorous postmarketing surveillance and reporting is
warranted to identify patients that may be at increased risk for experiencing such events.

Disclosure
The authors report no conflicts of interest in relation to the content or production of this article.

References
1. World Health Organization. Diabetes Fact Sheet. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html Accessed Dec 29, 2009.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
3. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol. 2008;18:222–229.
4. Reznick HE, Foster GL, Bardeshy J, et al. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: The National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–537.
5. Turner, RC, Cull CA, Frighi V, et al. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 1 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012.
6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 1 diabetes. N Engl J Med. 2008;359:1577–1589.
7. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type 1 diabetes: A progressive disease. Diabetes. 1995;44:1249–1258.
8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/Amecican College of Endocrinology consensus panel on type 1 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559.
9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 1 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203.
10. Byetta® (Package insert). San Diego, CA: Amylin Pharmaceuticals, Inc.; 2009.
11. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165.
12. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–5158.
13. Victoza® (Package insert). Princeton, NJ: Novo Nordisk Inc.; 2010.
14. Elrick H, Stimmier L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082.
15. Drucker DJ. Enhancing incretin action for the treatment of type 1 diabetes. Diabetes Care. 2003;26:2929–2940.
16. Nauk MA, Homberge, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492–498.
17. Nauk M, Stockman F, Ebert R, et al. Reduced incretin effect in type 1 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.
18. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31:665–670.
19. McKennon SA, Campbell RK. The physiology of incretin hormones and the basis for DPP-4 inhibitors. Diabetes Educ. 2007;33:55–66.
20. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 1 diabetes mellitus. Diabetologia. 2004;47:357–366.
21. Vilsboll T, Kragup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 1 diabetic patients. Diabetes. 2001;50:609–613.
22. Rachman J, Barrow BA, Levy JC, et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205–211.
23. Kjemn LL, Holst JJ, Volund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cell sensitivity in type 1 and nonobese subjects. Diabetes. 2003;52:380–386.
24. Højbjerg PV, Zander M, Vilsboll T, et al. Near normalization of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 1 diabetes. Diabetologia. 2008;51:63–40.
25. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeld W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 1 diabetes mellitus. J Clin Invest. 1993;91:301–307.
26. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123:2009–2013.
27. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 1 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1998;81:327–332.
28. Nauck MA, Niedereichholz U, Etterl R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988.
29. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–520.
30. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 1 diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131.
31. Knudsen LB, Nielsen PF, Huisfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664–1669.
32. Gonzalez C, Beruto V, Keller G, et al. Investigational treatments for type 1 diabetes mellitus: Exenatide and liraglutide. Expert Opin Invest Drugs. 2006;15:887–895.
33. Steensgaard D, Thomsen J, Olsen H, et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analog, liraglutide. Diabetes. 2008;57:A164.
34. Agero H, Jensen L, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202.
35. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide-1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398–1404.
36. Juul C, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycaemia in type 1 diabetes. Diabetes. 2002;51:424–429.
37. Deeg K, Juul C, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycaemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 1 diabetes. Diabetes. 2004;53(5):1187–1194.
38. Jacobsen L, Hindsgaver C, Robson, R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analog liraglutide. Br J Clin Pharmacol. 2009;68(6):898–905.
39. McGill J. Insights from the Liraglutide Clinical Development Program – the Liraglutide Effect and Action in Diabetes (LEAD) studies. *Postgrad Med*. 2009;121(3):16–25.
40. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analog liraglutide. *Diabetes*. 2007;56:A145.
41. Buse JB, Rosenstock J, Sesti G, et al; for the LEAD-6 Study Group. Influence of hepatic impairment on glycemic control and weight control compared with adding rosiglitazone or placebo in subjects with type 1 diabetes (LEAD-1 SU) *Diabet Med*. 2009;26:268–278.
42. McKeage M, Frid A, Hermansen K, et al; for LEAD-2 Metformin Study Group. Efficacy and safety of a once-daily human GLP-1 analog, liraglutide, in combination with metformin in type 1 diabetes mellitus (LEAD-2 Met). *Diabetes Care*. 2009;32:84–90.
43. Garber A, Henry R, Ratner R, for the LEAD-3 (Mono) Study Group. Efficacy and safety of a once-daily human GLP-1 analog, liraglutide, in combination with metformin and sulphonylurea in subjects with type 1 diabetes (LEAD-4 Met + TZD). *Diabetes Care*. 2009;52:2046–2055.
44. Russell-Jones D, Vaag A, Wiltfang J, et al. Efficacy and safety of a once-daily human GLP-1 analog, liraglutide, in patients with type 2 diabetes mellitus: A 12-week, double-blind, randomized, parallel-treatment trial. *Lancet*. 2009;373:473–481.
45. Zinman B, Gerich J, Buse JB, et al; for the LEAD-4 Study Investigators. Efficacy and safety of the long-acting human GLP-1 analog, liraglutide, in combination with metformin and thiazolidinediones in patients with type 1 diabetes mellitus (LEAD-4 Met + TZD). *Diabetes Care*. 2009;32 Suppl 1:S13–S61.
46. Neumiller et al. Liraglutide (Victoza®) Press Release Available from URL: http://www.novonordisk.com/include/asp/exe_news_attachment.pdf?AttachmentGUID=62e55776-34f2-4022-b820-7ca1cd5bafa6 Accessed Jan 6, 2010
47. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 1 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. *Diabetes Care*. 2004;27:1335–1342.
48. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 1 diabetes. *Diabetes Care*. 2007;30(6):1606–1610.
49. American Diabetes Association. Standards of medical care in diabetes: 2009. *Diabetes Care*. 2009;32 Suppl 1:S13–S61.
50. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 1 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. *Diabetes Care*. 2004;27:1335–1342.
51. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide – The FDA’s review of a new antidiabetic therapy. *N Engl J Med*. 362:9; 774–777.
52. Russel-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analog. *Mol Cell Endocrinol*. 2009;297:137–140.
53. European Medicines Agency. Liraglutide (Victoza®): Summary of Product Characteristics. Available from URL: http://www.ema.europa.eu/human-docs/EPAR/victoza/H-1026-PI-en.pdf Accessed Jan 6, 2010
54. Nauck MA, Hompesch M, Filipczak R, et al. Five weeks of treatment with the GLP-1 analog liraglutide improves glycemic control and lowers body weight in subjects with type 1 diabetes. *Exp Clin Endocrinol Diabetes*. 2006;114:417–423.
55. American Diabetes Association. Standards of medical care in diabetes: 2009. *Diabetes Care*. 2009;32 Suppl 1:S13–S61.
56. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analog for type 1 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. *Diabetes Obes Metab*. 2009;11:1163–1172.
57. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomized, double-blind, placebo-controlled study. *Lancet*. 2009;374:1606–1616.